Trial Profile
First-in-human Clinical Study With RNA-Immunotherapy Combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumor Therapy in Triple Negative Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs BNT 114 (Primary) ; BNT 121 (Primary)
- Indications Adenocarcinoma; Early breast cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Acronyms MERIT; TNBC-MERIT
- Sponsors BioNTech
- 18 Jul 2023 Status changed from active, no longer recruiting to completed.
- 08 Feb 2021 Planned number of patients changed from 39 to 42.
- 08 Feb 2021 Planned End Date changed from 1 Nov 2020 to 1 Dec 2023.